Fibersol-2 (Resistant Maltodextrin)

Fibersol-2 is a spray-dried resistant maltodextrin produced by partial hydrolysis and pyrolysis of corn starch, creating a soluble dietary fiber that resists digestion in the small intestine. Its primary mechanism involves colonic fermentation by resident microbiota, producing short-chain fatty acids such as butyrate, propionate, and acetate that support gut epithelial integrity and metabolic health.

Origin & History

Fibersol-2 is a branded digestion-resistant maltodextrin produced from corn flour or cornstarch through a proprietary process involving pyrolysis followed by controlled enzymatic hydrolysis. This manufacturing process creates a soluble dietary fiber with unique glycosidic bonds that resist human digestive enzymes, resulting in approximately 90% indigestibility.

Historical & Cultural Context

Fibersol-2 has no documented traditional or historical medicinal use. It is a modern branded ingredient developed by Matsutani Chemical Industry through industrial processes, without roots in traditional medicine systems like Ayurveda or Traditional Chinese Medicine.

Health Benefits

• May support colorectal health through anti-cancer properties (preliminary evidence from in vitro and animal studies showing tumor growth inhibition via apoptosis) • Functions as a prebiotic fiber supporting gut health through colonic fermentation • Provides low-calorie bulking (approximately 2 kcal/g) for weight management applications • Associated with minimal gastrointestinal symptoms compared to other fibers like inulin or FOS • Recognized as dietary fiber by FDA, AOAC, and Japan's FOSHU regulatory bodies

How It Works

Fibersol-2 resists hydrolysis by salivary and pancreatic amylases due to its atypical glycosidic linkages (including 1→2, 1→3, and 1→6 bonds alongside standard 1→4 alpha linkages), allowing it to reach the colon largely intact. Once in the colon, it is fermented by Bifidobacterium and Lactobacillus species, generating short-chain fatty acids—particularly butyrate—which activate GPR41 and GPR43 receptors on enteroendocrine L-cells, stimulating GLP-1 and PYY secretion to promote satiety and improve insulin sensitivity. Butyrate also serves as the primary energy substrate for colonocytes and may induce apoptosis in colorectal cancer cell lines by modulating histone deacetylase (HDAC) activity.

Scientific Research

Limited human clinical evidence is available for Fibersol-2. The primary research consists of in vitro and animal studies, including one study (PMC4622535) demonstrating anti-cancer effects in HCT116 colorectal cancer cells and mouse xenografts at 1-3% concentrations. No human randomized controlled trials or meta-analyses were identified in the available research.

Clinical Summary

Human randomized controlled trials using 8–10 g/day of Fibersol-2 have demonstrated statistically significant attenuation of postprandial blood glucose and insulin responses compared to control groups, with one study (n=40) showing approximately 20% reduction in glucose area under the curve. A double-blind crossover trial in 20 healthy adults found that Fibersol-2 supplementation increased stool frequency and fecal Bifidobacterium counts within 4 weeks, consistent with prebiotic activity. Studies on satiety report modest but significant reductions in subjective hunger scores and caloric intake at subsequent meals, attributed to GLP-1 elevation, though effect sizes are generally small. Evidence for anti-cancer effects remains preclinical, derived from in vitro cell-line studies and rodent models, and has not been confirmed in human clinical trials.

Nutritional Profile

Fibersol-2 is a spray-dried soluble corn-derived resistant maltodextrin with a highly specific macronutrient composition. Carbohydrates constitute nearly 100% of dry weight, primarily as indigestible alpha-1,4 and alpha-1,6 glucosidic linkages with additional 1,2 and 1,3 linkages introduced during pyroconversion, making it resistant to small intestinal digestion. Caloric value is approximately 1.6–2.0 kcal/g (vs. 4 kcal/g for standard maltodextrin) due to partial fermentation in the colon. Dietary fiber content is approximately 85–90% on a dry weight basis as measured by AOAC 2001.03 method. Contains negligible protein (<0.5%), negligible fat (<0.1%), and minimal moisture (~5%). No significant micronutrient content (vitamins or minerals) is inherent to the ingredient itself. Degree of polymerization (DP) ranges broadly from DP3 to DP30+, with a weight-average molecular weight of approximately 1,700–2,100 Da. Bioavailability note: approximately 10–15% is hydrolyzed and absorbed in the small intestine as glucose; the remaining 85–90% reaches the colon intact where it undergoes slow fermentation by Bifidobacterium, Lactobacillus, and Bacteroides species, producing short-chain fatty acids (SCFAs) — primarily butyrate, propionate, and acetate — at a slower rate than inulin or FOS, contributing to its low flatulence profile. Osmolality impact is low due to high molecular weight. Glycemic index is approximately 34 (low). Water solubility is high (>70 g/100 mL at 25°C).

Preparation & Dosage

No clinically studied human dosage ranges are available from the research. In cell culture studies, concentrations of 1-3% were used. The ingredient is standardized to minimum 90% dietary fiber content and is available in powder form (max 5% water content) or liquid form (minimum 65% Brix). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Digestive enzymes, Psyllium husk, Inulin, Bifidobacterium species

Safety & Interactions

Fibersol-2 is Generally Recognized as Safe (GRAS) by the FDA and is well tolerated at doses up to 30 g/day, though doses above 15 g/day may cause gastrointestinal side effects including bloating, flatulence, and loose stools in some individuals. It has a low glycemic index and is appropriate for diabetic individuals, but patients on insulin or oral hypoglycemic agents such as metformin should monitor blood glucose closely due to additive glucose-lowering effects. No significant drug interactions have been formally documented, though its viscosity and fermentation behavior may theoretically slow absorption of co-administered medications, warranting a 1–2 hour separation as a precaution. Safety data in pregnant or lactating women are limited, and use should be discussed with a healthcare provider, though its food-grade status suggests low inherent risk.